298 related articles for article (PubMed ID: 28615947)
1. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
Cozzolino M; Galassi A; Conte F; Mangano M; Di Lullo L; Bellasi A
Ther Clin Risk Manag; 2017; 13():679-689. PubMed ID: 28615947
[TBL] [Abstract][Full Text] [Related]
2. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
5. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
6. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy.
Friedl C; Zitt E
Drug Des Devel Ther; 2018; 12():1589-1598. PubMed ID: 29910605
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
8. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
9. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
10. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?
Eidman KE; Wetmore JB
Semin Dial; 2018 Sep; 31(5):440-444. PubMed ID: 30009474
[TBL] [Abstract][Full Text] [Related]
11. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
[TBL] [Abstract][Full Text] [Related]
12. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis.
Wolf M; Block GA; Chertow GM; Cooper K; Fouqueray B; Moe SM; Sun Y; Tomlin H; Vervloet M; Oberbauer R
Clin Kidney J; 2020 Feb; 13(1):75-84. PubMed ID: 32082556
[TBL] [Abstract][Full Text] [Related]
13. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
[TBL] [Abstract][Full Text] [Related]
14. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
Dudar I; Shifris I; Dudar S; Kulish V
Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
[TBL] [Abstract][Full Text] [Related]
16. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T
Clin Ther; 2018 Dec; 40(12):2099-2111. PubMed ID: 30473399
[TBL] [Abstract][Full Text] [Related]
17. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; UreƱa-Torres P; Vervloet M; Block GA
Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of Parsabiv
Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
[TBL] [Abstract][Full Text] [Related]
19. Etelcalcetide for the treatment of secondary hyperparathyroidism.
Hamano N; Komaba H; Fukagawa M
Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.
Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Odani M; Akizawa T;
Clin Exp Nephrol; 2018 Apr; 22(2):426-436. PubMed ID: 28836058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]